Medical technology company Becton, Dickinson, and Company (NYSE: BDX) announced results for the final three months of fiscal 2023.
Fourth-quarter revenue increased 6.8% to $5.1 billion as reported and rose 5.9% on a currency-neutral basisRevenue from the base business, which excludes COVID-only diagnostic testing, grew 7.3% as reported and 6.3% currency-neutral Earnings from continuing operations were $0.53 per share in Q4, vs. $0.93 per share last yearEarnings from continuing operations, on an adjusted basis, came in at $3.42 per share, up 24.4% year-over-yearThe company expects fiscal year 2024 revenues to be in the range of $20.1 billion to $20.3 billionFull-year adjusted profit is expected to be between $12.70 per share and $13.00 per share
The post Earnings Summary: Becton, Dickinson, and Company reports Q4 2023 results first appeared on AlphaStreet.
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]